

09/397,550

-4-

PD-A0000180-66-DRK

REMARKS

Claims 1, 2-4, 10-11 and 23 remain in the application. Only Claims 1, 12 and 23 are in independent form. Reconsideration of the subject application as amended pursuant to and consistent with 37 C.F.R. §1.112 and in light of the remarks which follow are respectfully requested.

With the present response Applicants have corrected typographical errors found in the specification. Applicants enclose a set of modified pages of the description for the benefit of the Examiner.

Applicants have also corrected obvious errors found in the specification. The following clarifications are provided for the Examiner's benefit:

a) The error contained at page 4 line 24.

Point N°14 was referring to itself. This point thus obviously contains an error. Point 14 refers to a recombinant polypeptide. Point N°13 page 4 line 21 refers to a purified or isolated recombinant polypeptide comprising the amino acid sequence of secreted soluble $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunit polypeptide. By reading the specification it is obvious that point N°14 should refer to point N°13.

b) The error contained at page 20 line 26.

Page 20 line 26 relates to a polypeptide comprising an amino acid sequence having particular percentage of identity with cited amino acid sequences under which are SEQ ID N°4-6, SEQ ID N°10-12, SEQ ID N°16-17. However it refers to SEQ ID N°19 which is a DNA sequence corresponding to full length $\alpha_2\delta$ -2. This paragraph thus obviously contains an error. By reading the specification it is obvious that this paragraph should refer to SEQ ID N°18. This obvious correction is further demonstrated by the reading of page 20 line 34 of the specification which mentions SEQ ID N°4-6, SEQ ID N°10-12 and SEQ ID N°16-18 as being preferred amino acids sequences of the invention.

c) The error contained at page 31 line 20 and 25.

09/397,550

-5-

PD-A0000180-66-DRK

Example 11 relates to a nucleotide sequence encoding a soluble secreted mouse $\alpha_2\delta$ -3 deletion mutant of cited amino acid sequence. However it refers to SEQ ID N°25 which is a DNA sequence. This example thus obviously contains an error. By reading the specification it is obvious that this paragraph should refer to SEQ ID N°24. This obvious correction is further demonstrated by the reading of page 33 line 9-10.

In the following paragraph, Applicants first provide a summary of some of the key points of the present invention. This is followed by comments to the specific rejections set forth in the Office Action.

The invention relates to truncated $\alpha_2\delta$ calcium channel subunit cDNA sequences which encode soluble secreted polypeptides which lack a C-terminal portion of the corresponding native protein while retaining their calcium channel subunit properties.

The term "soluble secreted $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunit" is intended to designate polypeptide sequences which, when produced by a recombinant host cell, are secreted at least partially into the culture medium rather than remaining associated with the host cell membrane (see the specification at page 8 lines 5-9).

Full length $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunits are membrane associated and thus are not secreted soluble. Therefore full length $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunits are not part of the invention.

Preferably the secreted soluble $\alpha_2\delta$ calcium channel subunit are human $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 polypeptides. However, due to cross species homology for the $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunit, the C-terminal deletion may also be applied to other eukaryotic species.

The present application specifically discloses the following deletion mutants:

For human $\alpha_2\delta$ -2:

- a 1062 amino acid long mutant (see nucleic sequence SEQ ID N°1 and amino acid sequence SEQ ID N°4)

09/397,550

-6-

PD-A0000180-66-DRK

- a 1082 amino acid long mutant (see nucleic sequence SEQ ID N°2 and amino acid sequence SEQ ID N°5)
- a 1109 amino acid long mutant (see nucleic sequence SEQ ID N°3 and amino acid sequence SEQ ID N°6).

For human $\alpha_2\delta$ -3:

- a 1019 amino acid long mutant (see nucleic sequence SEQ ID N°7 and amino acid sequence SEQ ID N°10)
- a 1038 amino acid long mutant (see nucleic sequence SEQ ID N°8 and amino acid sequence SEQ ID N°11)
- a 1065 amino acid long mutant (see nucleic sequence SEQ ID N°9 and amino acid sequence SEQ ID N°12).

For human $\alpha_2\delta$ -4:

- a 304 amino acid long mutant (see nucleic sequence SEQ ID N°13 and amino acid sequence SEQ ID N°16)
- a 323 amino acid long mutant (see nucleic sequence SEQ ID N°14 and amino acid sequence SEQ ID N°17)
- a 350 amino acid long mutant (see nucleic sequence SEQ ID N°15 and amino acid sequence SEQ ID N°18).

The use of some of these mutants is further illustrated through the examples referring to SEQ ID N°23 which is a truncated $\alpha_2\delta$ -2 which corresponds to a 1109 amino acid long mutant to which a 6His tag has been added and the example relating to SEQ ID N°24 which is a $\alpha_2\delta$ -3 deletion mutant to which a 6His tag has been added.

Claims 1, 9 and 12 stand rejected under 35 U.S.C §112, first paragraph, because the specification, while enabling for nucleotides encoding SEQ ID NO: 20 and 22, does not reasonably provide enablement for a nucleic acid encoding any other polypeptide.

09/397,550

-7-

PD-A0000180-66-DRK

The objection against Claim 9 can now be withdrawn since this claim has been deleted.

With regard to Claims 1 and 12, Applicants respectfully submit that these claims refer to secreted soluble polypeptides of $\alpha_2\delta$ -2, $\alpha_2\delta$ -3, $\alpha_2\delta$ -4 subunit. It is to be noted that SEQ ID NO: 20 and SEQ ID NO: 22 refer to full length sequences and do not fall into the scope of Claim 1.

Truncated $\alpha_2\delta$ -2, $\alpha_2\delta$ -3, $\alpha_2\delta$ -4 subunits have been illustrated by 3 specific sequences respectively. The one skilled in the art has enough guidance to create other deletion mutants which are secreted soluble $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunit polypeptides which retain their voltage-dependent calcium channel properties. Experimentation will be necessary to determine the interest of using shorter or longer mutants but the skilled person has an expectation of success based on the initial guidance of the specification and hence no undue experimentation is necessary.

In view of the above, withdrawal of the rejection of Claims 1, 9 and 12 under 35 USC §112, first paragraph is respectfully requested.

Claims 2-3 and 5 stand rejected under 35 U.S.C §112, first paragraph, because the specification while being enabling for a polynucleotide encoding a substantially purified polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 20 and 22, does not reasonably provide enablement for a polynucleotide encoding a substantially purified variant having at least 90% amino acids sequence identity to SEQ ID NO 20 and 22. The specification does not enable any person skilled in the art to which it pertains or with which it is most nearly connected to make and use the invention commensurate in scope with these claims.

The objection against Claim 5 can now be withdrawn since this claim has been deleted.

09/397,550

-8-

PD-A0000180-66-DRK

In response, Applicants wish to point out that Claims 2 and 3 have been amended to clarify the types of amino acids substitutions which can be contemplated by the skilled person.

Amended Claim 2 is supported by the specification at page 20, line 36 to the end of page 21.

Amended Claim 3 is supported by the specification at page 20, line 36 to the end of page 21.

In view of amended Claims 2 and 3, withdrawal of the rejection of those claims under 35 USC §112, first paragraph is respectfully requested.

Claims 1, 7, 9 and 12 stand rejected under 35 USC §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regards as the invention.

The Examiner indicates that Claims 1, 9 and 12 are indefinite in that they only describe the peptide of interest by an arbitrary protein name, i.e., "alpha2delta-2" and that nothing in the claims distinctly identifies the protein.

The objection against Claim 9 can now be withdrawn since this claim has been deleted.

In response, Applicants wish to point out that protein names $\alpha_2\delta$ -2, $\alpha_2\delta$ -3, $\alpha_2\delta$ -4 are definite, per se, for one of ordinary skill in the art. As an example, Klugbauer et.al. (The Journal of Neuroscience, January 15, 1999, 19(2): 684-691) describe two forms of the full length calcium channel $\alpha_2\delta$ -2 subunit and one form of the full length calcium channel $\alpha_2\delta$ -3 subunit. Thus, the wording $\alpha_2\delta$ -2, $\alpha_2\delta$ -3, $\alpha_2\delta$ -4 provide adequate guidance as to the nature of the polypeptide which Applicants claim.

09/397,550

-9-

PD-A0000180-66-DRK

Furthermore, Applicants wish to point out that the $\alpha_2\delta$ -2, $\alpha_2\delta$ -3, $\alpha_2\delta$ -4 subunit polypeptides of the invention are defined as mammalian secreted soluble cerebral cortical voltage-dependant calcium channel subunit polypeptides. Thus Claims 1, 9 and 12 distinctly claim the subject matter of the invention.

In view of the above, withdrawal of the rejection of Claims 1, 9 and 12 under 35 USC §112, second paragraph, is respectfully requested.

The Examiner also indicates that Claims 7 and 9 are indefinite because they recite the term "stringent conditions" which is a conditional term and because some nucleic acids which might hybridize under conditions of moderate stringency for example would fail to hybridize under conditions of high stringency.

The objection against Claims 7 and 9 can now be withdrawn since these claims have been deleted.

Claims 1, 4 and 10-12 stand rejected under 35 USC §102(b). The Examiner explains that Wei et al. disclose a human α_2 calcium channel which is 100% identical to SEQ ID NO: 1.

In response Applicants provide herewith as Exhibit 1 a sequence alignment of the human α_2 calcium channel sequence disclosed in Wei et al. and SEQ ID NO: 1 disclosed in the present application.

This alignment shows that Wei et al. disclose a full length human $\alpha_2\delta$ -2 subunit polypeptide (5463 nucleotides (AF042792)) whereas SEQ ID NO: 1 of the present application is a truncated version of this full length polypeptide (3186 nucleotides). Thus the sequence of the α_2 calcium channel disclosed by Wei et al. is not the same sequence as sequence SEQ ID NO: 1. Therefore, the α_2 calcium channel disclosed by Wei et al. is not 100% identical to the sequence of SEQ ID NO: 1. Furthermore it is clear from this

09/397,550

-10-

PD-A0000180-66-DRK

analysis that Wei et al. does not disclose any form of truncated calcium channel subunit. Hence Claims 1, 4, 10-12 are novel over this prior art.

The amendment of Claim 4 results from a typographical error. Appropriate sequences to be incorporated in this claim are provided at page 10, lines 16-19 of the specification as filed.

In view of the arguments set forth above withdrawal of the rejection of Claims 1, 4 and 10-12 under 35 USC §102(b) is respectfully requested.

Claims 1, 6, 7 and 9-12 are rejected under 35 USC §102(b) as being anticipated by WO9504822.

The objection against Claims 6, 7 and 9 can now be withdrawn since those claims have been deleted.

The Examiner explains that Harpold et al. disclose the cloning and expression of human voltage gated calcium channel subunits thus anticipating Claim 1.

In response, Applicants wish to draw the attention of the Examiner to the fact that Claim 1 refers to secreted soluble voltage-dependent calcium channel $\alpha_2\delta$ -2, $\alpha_2\delta$ -3, $\alpha_2\delta$ -4 subunit polypeptides and not only to voltage gated Ca^{2+} subunits. Therefore, Harpold et al. do not disclose a purified or isolated nucleic acid encoding a mammalian secreted soluble cerebral cortical voltage-dependent calcium channel $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunit polypeptide of Claim 1.

In conclusion Claim 1 is not anticipated by Harpold et al.

In view of the arguments set forth above withdrawal of the rejection of Claims 1, 6, 7 and 9 under 35 USC §102(b) is respectfully requested.

09/397,550

-11-


PD-A0000180-66-DRK

In view of the foregoing, further and favorable action in the form of a Notice of Allowance is believed to be next in order, and such action is earnestly solicited.

The Commissioner is hereby authorized to charge any fees under 37.C.F.R §1.116 and 1.117 that may be required by this paper to Deposit Account No. 23-0455,

In the event the Examiner wishes to discuss any matter concerning this application, he is invited to communicate with the undersigned.

Respectfully submitted,



David R. Kurlandsky

Reg. No. 41,505

Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-7304

Fax (734) 622-1553

Attachment - Amended claims, Version with markings to show changes made
Exhibit 1

DK1P4389.doc

09/397,550

-12-

PD-A0000180-66-DRK

"Version with markings to show changes made."

Please amend Claims 2, 3 and 4 as follows:

Claim 2 (amended). A purified or isolated nucleic acid according to claim 1, comprising a polynucleotide having at least 90% identity with the sequence encoding :

- from amino-acid 1 to between amino-acids 1027 and 1062 of SEQ ID N°20 for $\alpha_2\delta$ -2,
- from amino-acid 1 to between amino-acids 984 and 1019 of SEQ ID N°22 for $\alpha_2\delta$ -3

wherein the differing nucleotides encode amino acids which are the same as the amino acids of the SEQ ID N°20 and SEQ ID N°22 through codon degeneracy or encode amino acids which are equivalent to the amino acids of SEQ ID N°20 and SEQ ID N°22 either by structural homology, by net charge or hydrophobicity similarity, such that the encoded polypeptide retains its specificity and affinity properties to the biological targets of the parent polypeptides.

Claim 3 (amended). A purified or isolated nucleic acid according to claim 1, having at least 90% identity with the sequence encoding :

- from amino-acid 1 to between amino-acids 1047 and 1062 of SEQ ID N°20 for $\alpha_2\delta$ -2,
- from amino-acid 1 to between amino-acids 1004 and 1019 of SEQ ID N°22 for $\alpha_2\delta$ -3

wherein the differing nucleotides encode amino acids which are the same as the amino acids of the SEQ ID N°20 and SEQ ID N°22 through codon degeneracy or encode amino acids which are equivalent to the amino acids of SEQ ID N°20 and SEQ ID N°22 either by structural homology, by net charge or hydrophobicity similarity, such that the encoded polypeptide retains its specificity and affinity properties to the biological targets of the parent polypeptides.

Claim 4 (amended). A purified or isolated nucleotide sequence according to claim 1 wherein said sequence is the sequence of SEQ ID N°1, SEQ ID N°2, SEQ ID N°3, SEQ ID N°7, SEQ ID N°8, SEQ ID N°9, SEQ ID N°13, SEQ ID N°14, or SEQ ID N°15[, SEQ ID N°19 or SEQ ID N°21].

Please delete Claims 5, 6, 7 and 9.

09/397,550

-13-

PD-A0000180-66-DRK

Please add new Claim 23.

Claim 23 (NEW). A purified or isolated nucleic acid having at least 90% identity with the nucleotide sequence of SEQ ID N°1, SEQ ID N°2, SEQ ID N°3, SEQ ID N°7, SEQ ID N°8, SEQ ID N°9, SEQ ID N°13, SEQ ID N°14, or SEQ ID N°15.

Exhibit 1
Sequence alignment of sequence SEQ ID N°1 of the patent
application and the sequence of the human alpha 2 calcium channel
disclosed by Wei et al. (AF042792)

```
SEQ_ID_N1.se
AF042792.seq          GCCAGCGCTGC
                      10

SEQ_ID_N1.se
AF042792.seq  AGGGAGATAGCAGCGCGAGCCCGCAGAGGCGCTGCGGCCCGTGACGCCCCGAGGCCCCC
                20      30      40      50      60      70

SEQ_ID_N1.se
AF042792.seq  TCGCGGAGAAGGCGGCGGCGGAGGAGGCGCGAGTTACCGCCCCGCGGCCCGCGCCCCCCC
                80      90     100     110     120     130

SEQ_ID_N1.se
AF042792.seq  TCCCCGCGGCGCGCGCATCTTGAATGGAACATGGCGGTGCGCGCTCGGACCTGCGGCGCC
                140     150     160     170     180     190

SEQ_ID_N1.se
AF042792.seq  TCTCGGCCCGGCCAGCGCGGACTCGCGGCCCTGGCGCCGCTGCGGCCCCACCCCTGGC
                200     210     220     230     240     250

SEQ_ID_N1.se
AF042792.seq  CCGGCACCCGCGCGCCGACGTCCGGGCCCGCGCCCGCTGTGGCTGCTGTGCGCGCTT
                260     270     280     290     300     310

SEQ_ID_N1.se
AF042792.seq  CTACCGCTGCTCGCGCGCCCGCGCGCTCTGCTACAGCTTCCCCAGCAGCACACGATG
                320     330     340     350     360     370

SEQ_ID_N1.se
AF042792.seq  CAGCACTGGGCCCCGCGTCTGGAGCAGGAGGTCCAGCGCGTGATGCGGATTTTGGAGGC
                380     390     400     410     420     430

SEQ_ID_N1.se
AF042792.seq  GTCCAGCAGCTCCGTGAGATTTACAAGGACAACCGGAACCTGTTCCAGGTACAGGAGAAT
                440     450     460     470     480     490

SEQ_ID_N1.se
AF042792.seq  GAGCCTCAGAAGTTGGTGGAGAAGGTGGCAGGGGACATTGAGAGCCTTCTGGACAGGAAG
                500     510     520     530     540     550

SEQ_ID_N1.se
AF042792.seq  GTTCAGGCCCTGAAGAGACTGGCTGATGCTGCAGAGAACTTCCAGAAAGCACACCGCTGG
                400     410     420     430     440     450
```

```
560      570      580      590      600      610
      460      470      480      490      500      510
SEQ_ID_N1.se CAGGACAACATCAAGGAGGAAGACATCGTGTACTATGACGCCAAGGCTGACGCTGAGCTG
AF042792.seq CAGGACAACATCAAGGAGGAAGACATCGTGTACTATGACGCCAAGGCTGACGCTGAGCTG
      620      630      640      650      660      670
      520      530      540      550      560      570
SEQ_ID_N1.se GACGACCCCTGAGAGTGAGGATGTGGAAAGGGGGTCTAAGGCCAGCACCCCTAAGGCTGGAC
AF042792.seq GACGACCCCTGAGAGTGAGGATGTGGAAAGGGGGTCTAAGGCCAGCACCCCTAAGGCTGGAC
      680      690      700      710      720      730
      580      590      600      610      620      630
SEQ_ID_N1.se TTCATCGAGGACCCAACTTCAAGAACAGGTCAACTATTTCATACGCGGCTGTACAGATC
AF042792.seq TTCATCGAGGACCCAACTTCAAGAACAGGTCAACTATTTCATACGCGGCTGTACAGATC
      740      750      760      770      780      790
      640      650      660      670      680      690
SEQ_ID_N1.se CCTACGGACATCTACAAAGGCTCCACTGTCTCCTCAATGAGCTCAACTGGACAGAGGCC
AF042792.seq CCTACGGACATCTACAAAGGCTCCACTGTCTCCTCAATGAGCTCAACTGGACAGAGGCC
      800      810      820      830      840      850
      700      710      720      730      740      750
SEQ_ID_N1.se CTGGAGAATGTGTTTCATGGAAAACCGCAGACAAGACCCCACTGCTGTGGCAGGTCTTC
AF042792.seq CTGGAGAATGTGTTTCATGGAAAACCGCAGACAAGACCCCACTGCTGTGGCAGGTCTTC
      860      870      880      890      900      910
      760      770      780      790      800      810
SEQ_ID_N1.se GGCAGCGCCACAGGAGTCACTCGCTACTACCGGCCACCCCGTGGCGAGCCCCCAAGAAG
AF042792.seq GGCAGCGCCACAGGAGTCACTCGCTACTACCGGCCACCCCGTGGCGAGCCCCCAAGAAG
      920      930      940      950      960      970
      820      830      840      850      860      870
SEQ_ID_N1.se ATCGACCTGTACGATGTCCGAAGGAGACCCCTGATATATCCAGGGGGCTCGTCACCCAAA
AF042792.seq ATCGACCTGTACGATGTCCGAAGGAGACCCCTGATATATCCAGGGGGCTCGTCACCCAAA
      980      990      1000      1010      1020      1030
      880      890      900      910      920      930
SEQ_ID_N1.se GACATGGTCATCATCGTGGATGTGAGTGGCAGTGTGAGCGGCTGACCCCTGAAGCTGATG
AF042792.seq GACATGGTCATCATCGTGGATGTGAGTGGCAGTGTGAGCGGCTGACCCCTGAAGCTGATG
      1040      1050      1060      1070      1080      1090
      940      950      960      970      980      990
SEQ_ID_N1.se AAGACATCTGTCTGCGAGATGCTGGACACGCTGTCTGATGATGACTATGTGAATGTGGCC
AF042792.seq AAGACATCTGTCTGCGAGATGCTGGACACGCTGTCTGATGATGACTATGTGAATGTGGCC
      1100      1110      1120      1130      1140      1150
      1000      1010      1020      1030      1040      1050
SEQ_ID_N1.se TCGTTCAACGAGAAGGCACAGCCTGTGTCTCATGCTTCACACACCTGGTGACGCCAATGTG
AF042792.seq TCGTTCAACGAGAAGGCACAGCCTGTGTCTCATGCTTCACACACCTGGTGACGCCAATGTG
      1160      1170      1180      1190      1200      1210
      1060      1070      1080      1090      1100      1110
SEQ_ID_N1.se CGCAACAAGAAGGTGTTCAAGGAAGCTGTGCAGGGCATGGTGGCCAAGGGCACCACAGGC
AF042792.seq CGCAACAAGAAGGTGTTCAAGGAAGCTGTGCAGGGCATGGTGGCCAAGGGCACCACAGGC
      1220      1230      1240      1250      1260      1270
```

```
1120 1130 1140 1150 1160 1170
SEQ_ID_N1.se TACAAGGCCGGCTTTGAGTATGCCTTTGACCAGCTGCAGAACTCCAACATCACTCGGGCC
AF042792.seq TACAAGGCCGGCTTTGAGTATGCCTTTGACCAGCTGCAGAACTCCAACATCACTCGGGCC
1280 1290 1300 1310 1320 1330
1180 1190 1200 1210 1220 1230
SEQ_ID_N1.se AACTGCAACAAGATGATCATGATGTTTACGGATGGTGGTGAGGACCGGTGCAGGACGTC
AF042792.seq AACTGCAACAAGATGATCATGATGTTTACGGATGGTGGTGAGGACCGGTGCAGGACGTC
1340 1350 1360 1370 1380 1390
1240 1250 1260 1270 1280 1290
SEQ_ID_N1.se TTTGAGAAGTACAATTGGCCAAACCGGACCGTGCGCGTGTCTTACTTTCTCCGTGGGGCAG
AF042792.seq TTTGAGAAGTACAATTGGCCAAACCGGACCGTGCGCGTGTCTTACTTTCTCCGTGGGGCAG
1400 1410 1420 1430 1440 1450
1300 1310 1320 1330 1340 1350
SEQ_ID_N1.se CATAACTATGACGTACACCGCTGCACTGGATGGCCTGTGCCAACAAGGCTACTATTTT
AF042792.seq CATAACTATGACGTACACCGCTGCACTGGATGGCCTGTGCCAACAAGGCTACTATTTT
1460 1470 1480 1490 1500 1510
1360 1370 1380 1390 1400 1410
SEQ_ID_N1.se GAGATCCCTTCCATCGGAGCCATCCGCATCAACACACAGGAATATCTAGATGTGTGGGC
AF042792.seq GAGATCCCTTCCATCGGAGCCATCCGCATCAACACACAGGAATATCTAGATGTGTGGGC
1520 1530 1540 1550 1560 1570
1420 1430 1440 1450 1460 1470
SEQ_ID_N1.se AGGCCCATGTGCTGGCAGGCAAGGAGGCCAAGCAGGTTTCACTGGACCAACGTGTATGAG
AF042792.seq AGGCCCATGTGCTGGCAGGCAAGGAGGCCAAGCAGGTTTCACTGGACCAACGTGTATGAG
1580 1590 1600 1610 1620 1630
1480 1490 1500 1510 1520 1530
SEQ_ID_N1.se GATGCACTGGGACTGGGGTTGGTGTAAACAGGGACCTCCCTGTTTCAACCTGACACAG
AF042792.seq GATGCACTGGGACTGGGGTTGGTGTAAACAGGGACCTCCCTGTTTCAACCTGACACAG
1640 1650 1660 1670 1680 1690
1540 1550 1560 1570 1580 1590
SEQ_ID_N1.se CATGGCCCTGGGGAAAGAAAGAACAGCTGATCCTGGGCGTGATGGGCATTGACGTGGCT
AF042792.seq CATGGCCCTGGGGAAAGAAAGAACAGCTGATCCTGGGCGTGATGGGCATTGACGTGGCT
1700 1710 1720 1730 1740 1750
1600 1610 1620 1630 1640 1650
SEQ_ID_N1.se CTGAATGACATCAAGAGGCTGACCCCAACTACAGCTTGGAGCCAACGGCTATGTGTTT
AF042792.seq CTGAATGACATCAAGAGGCTGACCCCAACTACAGCTTGGAGCCAACGGCTATGTGTTT
1760 1770 1780 1790 1800 1810
1660 1670 1680 1690 1700 1710
SEQ_ID_N1.se GCATTGACCTGAACGGCTACGTGTTGCTGCACCCCAATCTCAAGCCCCAGACCACCAAC
AF042792.seq GCATTGACCTGAACGGCTACGTGTTGCTGCACCCCAATCTCAAGCCCCAGACCACCAAC
1820 1830 1840 1850 1860 1870
1720 1730 1740 1750 1760 1770
SEQ_ID_N1.se TCCGGGAGCCTGTGACTCTGGACTTCCTGGATGCGGAGCTAGAGGATGAGAACAAAGGAA
AF042792.seq TCCGGGAGCCTGTGACTCTGGACTTCCTGGATGCGGAGCTAGAGGATGAGAACAAAGGAA
1880 1890 1900 1910 1920 1930
```

1780 1790 1800 1810 1820 1830
SEQ_ID_N1.se GAGATCCGTCGGGAGCATGATTGATGGCAACAAGGGCCACAAGCAGATCAGAACGTTGGTC
AF042792.seq GAGATCCGTCGGGAGCATGATTGATGGCAACAAGGGCCACAAGCAGATCAGAACGTTGGTC
1940 1950 1960 1970 1980 1990

1840 1850 1860 1870 1880 1890
SEQ_ID_N1.se AAGTCCCTGGATGAGAGGTACATAGATGAGGTGACACGGAACCTACACCTGGGTGCTATA
AF042792.seq AAGTCCCTGGATGAGAGGTACATAGATGAGGTGACACGGAACCTACACCTGGGTGCTATA
2000 2010 2020 2030 2040 2050

1900 1910 1920 1930 1940 1950
SEQ_ID_N1.se AGGAGCACTAACTACAGCCTGGGGCTGGTGCTCCACCTACAGCACCTTCTACCTCCAA
AF042792.seq AGGAGCACTAACTACAGCCTGGGGCTGGTGCTCCACCTACAGCACCTTCTACCTCCAA
2060 2070 2080 2090 2100 2110

1960 1970 1980 1990 2000 2010
SEQ_ID_N1.se GCCAATCTCAGTGACCAGATCCTGCAGGTCAAGTATTTTGAGTTCTCTGCTCCCGAGCAGC
AF042792.seq GCCAATCTCAGTGACCAGATCCTGCAGGTCAAGTATTTTGAGTTCTCTGCTCCCGAGCAGC
2120 2130 2140 2150 2160 2170

2020 2030 2040 2050 2060 2070
SEQ_ID_N1.se TTTGAGTCTGAAGGACACGTTTTCATTGCTCCCGAGAGTACTGCAAGGACCTGAATGCC
AF042792.seq TTTGAGTCTGAAGGACACGTTTTCATTGCTCCCGAGAGTACTGCAAGGACCTGAATGCC
2180 2190 2200 2210 2220 2230

2080 2090 2100 2110 2120 2130
SEQ_ID_N1.se TCAGACAACAACACCGAGTTCTGAAAACTTTATTGAGCTCATGGAGAAAGTGACTCCA
AF042792.seq TCAGACAACAACACCGAGTTCTGAAAACTTTATTGAGCTCATGGAGAAAGTGACTCCA
2240 2250 2260 2270 2280 2290

2140 2150 2160 2170 2180 2190
SEQ_ID_N1.se GACTCCAAGCAGTGCAACAACCTTCCTTCTGCACAACCTGATCTTGGACACGGGCATCAGC
AF042792.seq GACTCCAAGCAGTGCAACAACCTTCCTTCTGCACAACCTGATCTTGGACACGGGCATCAGC
2300 2310 2320 2330 2340 2350

2200 2210 2220 2230 2240 2250
SEQ_ID_N1.se CAGCAGCTGGTAGAGCGTGTGTGGAGGGACCGAGTCTCAACACGTACAGCCTACTGGCC
AF042792.seq CAGCAGCTGGTAGAGCGTGTGTGGAGGGACCGAGTCTCAACACGTACAGCCTACTGGCC
2360 2370 2380 2390 2400 2410

2260 2270 2280 2290 2300 2310
SEQ_ID_N1.se GTGTTGCTGCCACAGACGGTGGCATCACCCGAGTCTTCCCAACAAGGCAGCTGAGGAC
AF042792.seq GTGTTGCTGCCACAGACGGTGGCATCACCCGAGTCTTCCCAACAAGGCAGCTGAGGAC
2420 2430 2440 2450 2460 2470

2320 2330 2340 2350 2360 2370
SEQ_ID_N1.se TGGACAGAGAACCCTGAGCCCTTCAATGCCAGCTTCTACCGCCGAGCCTGGATAACCAAC
AF042792.seq TGGACAGAGAACCCTGAGCCCTTCAATGCCAGCTTCTACCGCCGAGCCTGGATAACCAAC
2480 2490 2500 2510 2520 2530

2380 2390 2400 2410 2420 2430
SEQ_ID_N1.se GTTATGCTTCAAGCCCCACACAGGATGCCCTGTTAAGGCCGCTGGAGCTGGAGAAT
AF042792.seq GTTATGCTTCAAGCCCCACACAGGATGCCCTGTTAAGGCCGCTGGAGCTGGAGAAT
2540 2550 2560 2570 2580 2590

2440 2450 2460 2470 2480 2490
SEQ_ID_N1.se GACACTGTGGGCATCCTCGTCAGCACAGCTGTGGAGCTCAGCCTAGGCAGGCGCACACTG
AF042792.seq GACACTGTGGGCATCCTCGTCAGCACAGCTGTGGAGCTCAGCCTAGGCAGGCGCACACTG
2600 2610 2620 2630 2640 2650

2500 2510 2520 2530 2540 2550
SEQ_ID_N1.se AGGCCAGCAGTGGTGGGCGTCAAGCTGGACCTAGAGGCTTGGGCTGAGAAGTTCAAGGTG
AF042792.seq AGGCCAGCAGTGGTGGGCGTCAAGCTGGACCTAGAGGCTTGGGCTGAGAAGTTCAAGGTG
2660 2670 2680 2690 2700 2710

2560 2570 2580 2590 2600 2610
SEQ_ID_N1.se CTAGCCAGCAACCGTACCCACCAAGACCAGCCTCAGAAGTGCGGCCCCAACAGCCACTGT
AF042792.seq CTAGCCAGCAACCGTACCCACCAAGACCAGCCTCAGAAGTGCGGCCCCAACAGCCACTGT
2720 2730 2740 2750 2760 2770

2620 2630 2640 2650 2660 2670
SEQ_ID_N1.se GAGATGGACTGCGAGGTTAAACAATGAGGACTTACTCTGTCTCTCTCATTGATGATGGAGGA
AF042792.seq GAGATGGACTGCGAGGTTAAACAATGAGGACTTACTCTGTCTCTCTCATTGATGATGGAGGA
2780 2790 2800 2810 2820 2830

2680 2690 2700 2710 2720 2730
SEQ_ID_N1.se TTCCTGGTCTGTCAAACCAAGACCATCAGTGGGACCAAGTGGGCGAGTTCTTCAGTGAG
AF042792.seq TTCCTGGTCTGTCAAACCAAGACCATCAGTGGGACCAAGTGGGCGAGTTCTTCAGTGAG
2840 2850 2860 2870 2880 2890

2740 2750 2760 2770 2780 2790
SEQ_ID_N1.se GTGGATGCCAACCTGATGCTGGCACTCTACAATAACTCTTCTACACCCGCAAGGAGTCC
AF042792.seq GTGGATGCCAACCTGATGCTGGCACTCTACAATAACTCTTCTACACCCGCAAGGAGTCC
2900 2910 2920 2930 2940 2950

2800 2810 2820 2830 2840 2850
SEQ_ID_N1.se TATGACTATCAGGCAGCCTGTGCCCCCTCAGCCCCCTGGCAACCTGGGTGCTGACCCCCG
AF042792.seq TATGACTATCAGGCAGCCTGTGCCCCCTCAGCCCCCTGGCAACCTGGGTGCTGACCCCCG
2960 2970 2980 2990 3000 3010

2860 2870 2880 2890 2900 2910
SEQ_ID_N1.se GGTGTCTTTGTGCCCCCGTTGCAGATTTCTTAACCTGGCCTGGTGAGCTCTGTCTGCC
AF042792.seq GGTGTCTTTGTGCCCCCGTTGCAGATTTCTTAACCTGGCCTGGTGAGCTCTGTCTGCC
3020 3030 3040 3050 3060 3070

2920 2930 2940 2950 2960 2970
SEQ_ID_N1.se GCTGTGTCCTGTTCCAGCAGCTTCTCTACGGCCTCATCTACCACAGCTGGTTCCAAGCA
AF042792.seq GCTGTGTCCTGTTCCAGCAGCTTCTCTACGGCCTCATCTACCACAGCTGGTTCCAAGCA
3080 3090 3100 3110 3120 3130

2980 2990 3000 3010 3020 3030
SEQ_ID_N1.se GACCCCGCGGAGGCGGAGGCGGAGCCCGAGACGCGGAGAGCAGCTGCGTCATGAAACAG
AF042792.seq GACCCCGCGGAGGCGGAGGCGGAGCCCGAGACGCGGAGAGCAGCTGCGTCATGAAACAG
3140 3150 3160 3170 3180 3190

3040 3050 3060 3070 3080 3090
SEQ_ID_N1.se ACCCAGTACTACTTCGGCTCGGTAAACGCCCTCTACAAGCCATCATCGACTGCGGAAAC
AF042792.seq ACCCAGTACTACTTCGGCTCGGTAAACGCCCTCTACAAGCCATCATCGACTGCGGAAAC
3200 3210 3220 3230 3240 3250

SEQ_ID_N1.se 3100 3110 3120 3130 3140 3150
TGCTCCAGGCTGTTCACGCGCAGAGACTGACCAACACCAATCTTCTTTGTGGTGGCC
AF042792.seq 3260 3270 3280 3290 3300 3310
TGCTCCAGGCTGTTCACGCGCAGAGACTGACCAACACCAATCTTCTTTGTGGTGGCC

SEQ_ID_N1.se 3160 3170 3180
GAGAAGCCGCTGTGCAGCCAGTGCAGGCTGGCCGG
AF042792.seq 3320 3330 3340 3350 3360 3370
GAGAAGCCGCTGTGCAGCCAGTGCAGGCTGGCCGGCTGCTGCAGAAGGAGACGCACTGC

SEQ_ID_N1.se
AF042792.seq 3380 3390 3400 3410 3420 3430
CCAGCCGACGCCCCGAGCAGTGTGAGCTAGTGCAGAGACCGGATACCGGAGAGGCCCCG

SEQ_ID_N1.se
AF042792.seq 3440 3450 3460 3470 3480
CACATCTGCTTCGACTACAACGCGACAGAAGATACCTCAGACTGTGGCC

SEQ_ID_N1.se
AF042792.seq 3490 3500 3510 3520 3530 3540
GCGGGGCTCTCTCCCGCCGCTGCTGGGCTCTCTGCTCTCCCTGCAACTGCTGCTCTCTCC

SEQ_ID_N1.se
AF042792.seq 3550 3560 3570 3580 3590 3600
TGGGCTGCGCCCGCCGCGCAGCCTCAAGTCTCTGCTCCAGCCTCTCGCCGCTCTGAG

SEQ_ID_N1.se
AF042792.seq 3610 3620 3630 3640 3650 3660
CACCTGCCCCACCCACCTCCACTCCACCTCACCCGCTCTCTGCTCTTCCACCT

SEQ_ID_N1.se
AF042792.seq 3670 3680 3690 3700 3710 3720
CTGCCCCCACTCCCGCTTAGAGCTCTGCTCTCTCTCACTGAAGGACCTGAGCTGG

SEQ_ID_N1.se
AF042792.seq 3730 3740 3750 3760 3770 3780
CCAGCCCTGAGAGTCTGCTGCGCTTGGGATGGGAGTCCCAAAGCGGACCGCCCA

SEQ_ID_N1.se
AF042792.seq 3790 3800 3810 3820 3830 3840
GTGTTTGGCACCCAAATCACATCTCACCTCCGAAGTGTCAAGTGTCCCCAGACCTTC

SEQ_ID_N1.se
AF042792.seq 3850 3860 3870 3880 3890 3900
TGGCTGCTGGGCTCCCCCAGTGGGATGGGACAGGAGGCCACCGCACTGGTGCCAAA

SEQ_ID_N1.se
AF042792.seq 3910 3920 3930 3940 3950 3960
ACAGGCTCTGCTGCGCCCTTCTGAGGCTGCTATGTTGGGGGGACCTGCTCA

SEQ_ID_N1.se
AF042792.seq GCTGACCCGCTCTCTGCCCCACCCAAAGCCAAACTTGGTTCTGTGAGAATAGTGGAG

3970 3980 3990 4000 4010 4020

SEQ_ID_N1.se

AF042792.seq GAAGGTGAGATGGCCAGTTTGAAGCCTGTGCCTCCAGCTTAAATCCTAGCAGGAGAGAG
4030 4040 4050 4060 4070 4080

SEQ_ID_N1.se

AF042792.seq GCTCTGGGGCAGCCCCATGGGCTCCTGCCCTTTTCAGGCCTACAGCCACATCCCCAAGC
4090 4100 4110 4120 4130 4140

SEQ_ID_N1.se

AF042792.seq TCACCAGGTGTGAGGATAGTCACAGTGATACCACTTCAGACACTACCCCATATACACCTG
4150 4160 4170 4180 4190 4200

SEQ_ID_N1.se

AF042792.seq GAACATTGAGGATGGAACTGGACTCAGATTTCAGACATACCCCACTGGGCACACGCACAAA
4210 4220 4230 4240 4250 4260

SEQ_ID_N1.se

AF042792.seq CACACACTATGGGGTGGGGTGGGTGTAGGGCTTACAAAGCCTTACACAGGGCGAGGG
4270 4280 4290 4300 4310 4320

SEQ_ID_N1.se

AF042792.seq GTTGCTGGGAGGGTTGGCACCTGCACACTCCATCTCTGCTCACCACCTGCCTCTAATCT
4330 4340 4350 4360 4370 4380

SEQ_ID_N1.se

AF042792.seq GAGCTGCAGCCTGGCTGGTCTCCCATTTCTAAAGCTGAATGTCAAACAGTCCCAATGC
4390 4400 4410 4420 4430 4440

SEQ_ID_N1.se

AF042792.seq TGGGGCAGGGGGTGAAGAACCCTCTGTCCCACTCCCTAGCCACCACTGTCTCCCAAGTGCC
4450 4460 4470 4480 4490 4500

SEQ_ID_N1.se

AF042792.seq CCTCACCTCTCCAGGTGCTCATTGTAACCATTTCTCACTAGTGTGAGGCCCCCACTGGG
4510 4520 4530 4540 4550 4560

SEQ_ID_N1.se

AF042792.seq ACCACATGCCACTGCCTGCACCTTTCCGGCAGAGGAACCCCAACAGACATCACCTTTGC
4570 4580 4590 4600 4610 4620

SEQ_ID_N1.se

AF042792.seq CTAGCAGGGGTGACTTTGTCTCTCTCCTGGCTGGGCCATCCTTCGGCCAATCTGGCCCTTA
4630 4640 4650 4660 4670 4680

SEQ_ID_N1.se

AF042792.seq CACACTCAGGCCTGTGCCCACTCCCTATCTCTTCCCACTCCCTACACACACTCCCTGC
4690 4700 4710 4720 4730 4740

SEQ_ID_N1.se

AF042792.seq TTGCAGGAGGCCAACTGTCCCTCCCTGTGCTGAACACACACACACACACACAGG
4750 4760 4770 4780 4790 4800

'AF042792.seq TTC